Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib
By asianet
— Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency — This submission follows the grant of accelerated assessment allowing an expedited review for leniolisib from a standard 210 days to 150 days Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: … Continued